BioVie (BIVI) Registration filing summary

Company overview and business model

• Clinical-stage company focused on developing innovative drug therapies for neurological, neurodegenerative disorders, and advanced liver disease.

• Lead asset bezisterim (NE3107) targets inflammation-driven insulin resistance, with potential applications in Alzheimer's, Parkinson's, and long COVID.

• Pipeline includes BIV201 for liver cirrhosis and ascites, with FDA Fast Track and Orphan Drug designations.

Financial performance and metrics

• As of June 8, 2026, aggregate market value of outstanding common stock held by non-affiliates was approximately $12.5 million, based on 7,292,401 shares at $1.72 per share.

• No dividends have been declared or paid; all earnings are retained for business development and growth.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, capital expenditures, R&D, and potential acquisitions.

• Specific allocation and timing will depend on funding requirements and capital availability.